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Cognitive decline is a common feature of ageing, sometimes gentle at other times less so. It manifests as a wide
spectrum from cognitive impairment that is not dementia to Alzheimer’s disease and to the much rarer but potentially
enlightening familial forms. The Lancet’s 1996 international conference was held in Edinburgh, UK, on April 25 and
26. The meeting brought together epidemiologists, geneticists, neuropsychologists, neuropathologists, clinicians,
and imaging specialists, and those concentrating on the social and ethical aspects of the dementias. Half the con-
ference was devoted to discussion that crossed specialty boundaries. This report highlights the major areas of agree-
ment and controversy and points to opportunities for future multidisciplinary research.
The spectrum of cognitive impairment is addressed in four
main areas, following the conference format-namely,
Epidemiology; Genetics and Biomarkers; Neuroimaging,
Neuropsychology, and Neuropathology; and Social
Aspects. Selected references are provided for further
background reading.
Epidemiology
Many studies have investigated the prevalence of
dementia in the community.I-3 Once case-finding criteria
were standardised in the early 1980s, the population
prevalence of senile dementia above age 65 was
consistently reported to be about 5%. Vet, despite the vast
amount of data generated from prevalence, case-control
and incidence investigations, key epidemiological
questions await answers from studies now in progress. In
particular:
< What is the nature and prevalence of subtle degrees of
cognitive impairment (cognitive impairment no dementia,
CIND) as opposed to overt dementia?4
< What is the incidence of dementia/cognitive impairment
in the oldest old?
. What differences in incidence and prevalence exist
across different cultures, and why?
. How will the general-ie, cohort-effects of
cardiovascular and cerebrovascular risk reduction
influence future rates of cognitive impairment?
The most pressing issue is our remarkable lack of
understanding about the natural history of cognitive
decline. Is cognitive deterioration a continuous, age-
related process or is it a discrete disease pathology?5
Underlying this research question is a more profound,
almost philosophical issue: what is normal ageing?
Knowledge about natural history demands longitudinal
study designs. The rapid acceleration in our
understanding of the genetics and neuropathology of the
dementias has enabled investigators to correlate age at
onset, socio-demographic variables, and symptoms with
data from psychometric and genetic testing,
neuroimaging, neuropathological examination, and
response to treatment. Practical measures of cognitive
decline must be built into such a research programme. It
is not enough to base natural history studies on a series of
abstract psychometric or biological variables if they have
little or no meaning in the functional realities-eg,
activities of daily living-for the persons concerned. Such
a programme is likely to require international
collaboration and pooling of resources.
This phenomenological approach should have two
further benefits. First, it will move the debate beyond
existing, and constraining, notions of dementia towards a
more empirically governed view of cognitive impairment.
Alzheimer’s disease and "vascular dementia" imply
independent and mutually exclusive disease patterns. This
conception of the dementias is now untenable. For
example, Skoog et a16 have recently shown the importance
of hypertension-a critical vascular risk factor-before the
time of onset of disability in patients with a diagnosis of
Alzheimer’s disease. Second, research into natural history
will overcome the limitations of cross-sectional studies
that identify risk factors for dementia (see table 1) but
which cannot tease out either temporal effects or the
complex interactions between risk factors. The temporal
sequence in cognitive change is important since non-
cognitive prodromal or coexisting symptoms of anxiety,
depression, or delusions may lead to diagnostic confusion
and are themselves treatable. Vulnerability factors-eg,
blood pressure and other biological life events-must also
be distinguished from potential protective factors, such as
APOE-E2 genotype, educational achievement, ongoing
intellectual activity, oestrogen, and use of non-steroidal
anti-inflammatory drugs.
Investigators also face several methodological obstacles.
For instance, the stability over time of the instruments
used to measure cognitive decline from psychometric
testing, with the risk of substantial learning effects, to
Table 1: Risk factors for Alzheimer’s disease
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Pane! 1: intervention strategies to Hm!t cognitive Impairment
Cognitive function exists as a continuum. The high-risk
approach aims to treat a small proportion of high-risk
’individuals (shaded) to shift their cognitive function to within
"normal" limits. A population strategy aims to reduce the
risk of the whole population.
neuropathological grading is largely unknown. And
measurement error is an often unacknowledged but
important source of bias. There is also a tension between
the needs of researchers and clinicians. Those conducting
research will wish to avoid labelling patients, but physicians
(and their patients) need these diagnostic categories to
advise, counsel, and plan management strategies.
Observational epidemiology will provide the foundation
for intervention strategies. Two approaches are possible
(see panel 1). First, a high-risk strategy will require an
effective drug to reduce the rate of cognitive decline. The
major research initiative in drug therapy for Alzheimer’s
disease still lies in developing agents to influence cerebral
cholinergic systems-eg, acetylcholinesterase inhibitors
and selective cholinergic agonists. An attractive alternative
approach is to modify overall population risk-eg, by
antihypertensive therapy.
However, before randomised clinical trials can proceed,
there are substantial difficulties in study design to be
resolved. For example, what should be the appropriate
primary outcome measures to judge efficacy? Improved
functional performance, to be sure, but other variables
such as imaging end-points may also be important. How
does one estimate a likely size effect of a given treatment?
How should one stratify the study population? By
genotype or with other variables-eg, age at onset, blood
pressure, or educational level? And how will trialists
address informed consent in a population with perhaps
severe cognitive impairment? Two stages to a clinical trial
programme are likely. First, there will be smaller
exploratory trials with strict eligibility criteria, which aim
to gather data on efficacy. These studies will be driven by
hypotheses generated from longitudinal surveys. Second,
larger, more pragmatic clinical trials will follow. These will
have wide inclusion criteria and will look at effectiveness,
acceptability, compliance, and cost. It is likely to be some
time before these larger trials will be warranted.
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Genetics and biomarkers
There is more to the genetics of Alzheimer’s disease than
the susceptibility allele APOE-E4, and it seems inevitable
that other susceptibility genes and, possibly, other autoso-
mal dominant genes will be found. Those we know about
are summarised in panel 2, and are reviewed elsewhere.6
The current position on the place of APOE genotyp-
ing-"maybe" to using it to assist in an already suspected
diagnosis of Alzheimer’s but "no" to its use to screen
healthy individuals for future risk-has been recently sum-
marised in a consensus statement.’ 1
The discovery of autosomal dominant gene mutations in
familial Alzheimer’s disease has excited research workers
not because they explain a high proportion of dementia
but because, once the functions of the normal gene prod-
ucts are known, light may be thrown on biological mecha-
nisms of Alzheimer’s disease-therapeutic targets being
the ultimate objective. Their scientific contribution may
thus be out of proportion to the incidence of the muta-
tions-as happened with the Li-Fraumeni cancer syn-
drome and p53, for example.
Molecular genetics (in families) and population genetics
is a complementary process in Alzheimer’s disease-as it
has proved to be in the genetics of breast cancer and Tay-
Sachs disease. Clinicians should be encouraged to ask
about family size and history in patients with dementia.
They must be attuned to picking up familial aggregations
(research indicates that close to 50% of Alzheimer cases
have at least one first-degree relative with dementia). New
susceptibility genes/factors will probably be found but they
Panel 2: Familial Akheimer’s disease genes and other genetic
.influences
APP = amyloid precursor protein.2 On chromosome 21;
autosomal dominant; four mutations identified so far. Early
onset (40-65 years); 20 families known to date.
PS-1 (or S182) = preseniiin-1. On chromosome 14; autosoma)
dominant; 28 mutations. Early onset (30-55); less than 100
families. -
PS-2 (or STM2) = presenilin-2. On chromosome 1; autosomal
dominant with variable penetrance; three mutations. Wide
range of age of onset (40-90); three big families, one being
the Volga-German kindreds.
APOE = apolipoprotein-E.5 On chromosome 19; three common
potymorphisms known as alleles e2, E3, and e4 (el is very
rare). Possession of one or two e4 alleles certainly a risk
factor for Alzheimer’s disease; e2 probably protective. Age of
onset from 40 to very old age.
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have to be evaluated in the light of APOE-genotype-specif-
ic distributions of those factors.
Major ways of subdividing clinical phenotypes in
Alzheimer’s disease include APOE status and, albeit with
less certainty, age of onset. We do not know how much of
all dementia is genetic. Classic teaching says no more than
10%. Today, the known susceptibility allele and mutations
can explain a higher proportion of Alzheimer’s disease.
And in non-Alzheimer’s dementia we have Huntington’s
disease and the prion disease as examples with known
genetic aetiology.
We do not know what the normal gene products of APP,
PS-1, and PS-2 do-or what, in the brain, apolipoprotein-
E does or even where it is made. However, there are sug-
gestions-eg, altered processing of amyloid precursor pro-
tein (APP), interference in the "notch" signalling pathway
determining cell fate during development, hinted at by
sequence homologies in the well-studied worm Caenor-
habditis elegans (PSl l2); and calcium homoeostasis.
Research emphases are:
0 We must find the other genes-and the functions of
those already known.
0 We need proper epidemiology, including longitudinal
design and necropsy confirmation, to measure relative
risks and to determine the sensitivity and specificity of
APOE genotyping.
 Future research should emphasise pathological confir-
mation and investigate the correlates of decline in the
brain.
* The case-definition of Alzheimer’s disease has served
well for 10-12 years but now needs a new look with a view
to working diagnoses rather than "gold standards".
 Interactions of APOE genotype and drug response
should be further explored.
 Environmental interactions (eg, with previous head
injury and virus infections) have to be investigated.
 Better animal models are needed to study mechanisms
and to screen for therapeutic agents. We have a mouse
model for amyloid-containing plaques (but no tangles), the
"knockout" mouse (for APP and APOE), and a possible
model for spontaneous Alzheimer-like neuropathology
(Microcebus murinus).
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Neuroimaging, neuropsychology, and
neuropathology
For clinicians, the challenge of the dementias begins with
the characterisation of normal brain ageing. By means of
neuropathological, neuropsychological, and neuroimaging
techniques we are now moving towards a definition of
normality; without that knowledge, defining a threshold of
dementia is impossible.
The effect of age alone is unknown but probably less
than has been assumed previously. Our concepts of
normal brain ageing have been based on "contaminated"
samples of so-called normal elderly individuals-in other
words, the control or reference populations have reflected
responder and survivor biases and have very probably
included subclinical or prodromal cases.l Age is associated
with changes in speed-related tasks, but elderly people can
compensate successfully. By using various cues and taking
a little longer, they can live virtually normal lives. The
learning and practice effects have been seriously
underestimated.
A severe hindrance to the assessment of normal ageing
has been the reliance on cross-sectional data.
Longitudinal studies are essential for this purpose, and
obtaining data from informants is a key component of any
such investigation. Longitudinal neuroimaging studies
’p<O.05.
Table 2: Sydney Older Persons Study: motor slowing and cog-
nitive decline at 3-year follow-up
Panel 3: Pathologies causing age-associated cognitive - 
,’, ’,’
decline  , . &deg;-._:-,. -.,.-_ .. ’. :Prodromat Alzheimer’s disease =- ..- . "c,’ r - ---- _ . - --:--
Multfple subcorticat ischaemia/infarction ,
Age-related non-hypertensive smatt-:ve$1 disease -
Lewy body disease (Lewy bodies are eosinophilic inclusions
ongtnatty described in idiopathic Parkinson’s dtsease, andriginall cribe(i idiopathic Parkinson’s  disease, a d
,also found in elderly- -person -s with- ii-O ievi4 -ence of ’ 
"
neuropsycMatfte disorder) , 
’ 
" 
,
"Normal" ageing? 
, /,
are also essential to distinguish between normal and
disease according to rate of change. Such studies can
show, for example, hippocampal volume loss with
magnetic resonance imaging (MRI) at the pre-dementia
stage in those with progressive cognitive decline. At a
neuropathological level in normal ageing brains there is
no reduction in hippocampal volume by comparison with
Alzheimer’s disease, or in any cortical volumes or in any
grey matter, and no age-related neuronal loss in the
hippocampus. The only volume decline in normal ageing
is minor loss of frontal white matter. 3
Although memory changes are the identifier of
impairment they are only one component.5 Impairment
must be measured in relation to decline from previous
performance at several levels-eg, behaviour, morphology,
motor function, and cognition. A preliminary analysis of
the 3-year incidence data on the first 199 individuals
followed up in the Sydney Older Persons Study (a
random sample of 537 people aged 75 or more) showed
that gait ataxia and motor slowing (table 2) were strong
predictors of later cognitive decline and dementia.4 There
is a tendency to consider impairment in terms of discrete
diagnoses. Clinically, however, there is an urgent need to
consider interactive disorders such as Alzheimer’s disease,
vascular abnormalities, Lewy body disease, and others.
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The pathologies causing age-associated cognitive decline
are shown in panel 3. To regard these as mutually
exclusive entities may make for tidy research projects but
will do little for real understanding of brain impairment.
The first step for further research is to refine the tools
that we already use. Thus:
 Neuropathological assessment should be based on
standardised histological criteria. There is good reason for
neuropathologists to devise such criteria "blind"-ie,
without knowledge of clinical evaluation or results of
imaging procedures.
w Similarly for neuropsychology, we need to understand
the psychometric properties of the various tests that are
commonly used. For example, what is the mini mental
state examination really measuring?
 The neuroimaging net needs to be cast more widely to
include all brain areas.
 Longitudinal neuropsychological and neuroimaging
studies, with neuropathology, are critical, and interactive
research projects are another key element.
w There has been considerable discussion of the
association between education and cognitive decline, and
further research could usefully be directed towards
correlations between factors such as baseline intelligence,
level of education, health, and social class.
Once this information has been accrued one could
envisage a multifactor intervention trial in normal healthy
individuals, the interventions reflecting biological and
behavioural rationale and with due knowledge of any
possible toxicity. 6
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Social aspects
"More than the too excellent skills of the metaphysician, it is
the dementias ... the breakdowns in mental skills which are
really suited ’to reveal’ us to ourselves."
Henri Michaux’
In its advanced stages dementia sometimes seems a
dehumanising disorder. It challenges our deepest
preconceptions about human nature, the basis of
consciousness, the freedom of the will, and personhood.
Despite the work of philosophers and medical ethicists
such as Harris (who defined a person as "a creature
capable of valuing its own existence"2), a framework for a
rational approach to the social, ethical, and legal aspects
of the dementias still eludes us.
Dementia takes about 7 years to progress to the
advanced stages, which is when the real challenges of
dealing with a progressive, irreversible condition confront
the carers at home and the medical carers. Caring for
people with dementia includes caring for the carers. The
features that cause stress in carers are wandering,
aggression, repetitive questioning, sleep disturbance,
incontinence, apathy, depression, pychosis, sexual
disinhibition, and poor eating habits;’ these are seen in all
cultures. The medical profession knows much about
dementia and ways to help carers, but this knowledge
needs to be applied in the community and passed on to
the carers. Counselling, day care for the person with
dementia, courses for carers, education, self-help groups,
respite care, and inpatient admissions are ways of relieving
the burden of caring for someone with dementia. These
interventions could be complementary to but should not
undermine the coping mechanisms (eg, accentuation of
positive aspects, emphasis on moral duty) of the carer.
Intervention strategies and instruments to measure the
level of stress and outcome of interventions are used with
proven success in other domains of psychiatry, such as
schizophrenia, and can be applied in dementia. They can
be used to create more effective interventions to help
carers to cope, such as community care programmes,
which help to delay institutionalisation of the person with
dementia, and improvement in the mental and physical
health of carers. The success of these interventions can
then be evaluated by the outcome measures (duration of
caregiving, improvement in carer’s health).
Although there is no effective treatment for people with
dementia, clearly, there are reversible dementias (eg,
hypothyroid) and many clinicians feel that even irrevers-
ible ones are treatable psychosocially. In the short-term
more effective drugs for symptoms will probably appear,
to be followed by more profound interventions to slow
progression. However, we should clarify stage-specific
therapeutic goals. Do we want to use drugs to enhance
the thinking of persons with cognitive impairment, no
dementia? Do we want to slow progression in an
individual who can no longer recognise their spouse of 50
years? At the heart of our discussion of desirable
treatment outcomes will be further consideration of the
quality of life of both patients and carers. It is especially
important that we develop ways to assess the quality of life
of patients so as not to exclude them from input into their
treatment plans. We must also look for new ways to be
more effective in drug development.
Cognitive training early in the illness does seem to help,
as assessed by quality of life measurements. A welcome
spin-off is that their carers’ quality of life also improves
(figure).
Figure: Effect of cognitive training on quality of life in people
with dementia and their caregivers
t1=baseline, t2=12 months later, CT=cognitive training
(Presented at the conference by D Meier, Basel, Switzerland.)
1306
The pathologies causing age-associated cognitive decline
are shown in panel 3. To regard these as mutually
exclusive entities may make for tidy research projects but
will do little for real understanding of brain impairment.
The first step for further research is to refine the tools
that we already use. Thus:
 Neuropathological assessment should be based on
standardised histological criteria. There is good reason for
neuropathologists to devise such criteria "blind"-ie,
without knowledge of clinical evaluation or results of
imaging procedures.
w Similarly for neuropsychology, we need to understand
the psychometric properties of the various tests that are
commonly used. For example, what is the mini mental
state examination really measuring?
 The neuroimaging net needs to be cast more widely to
include all brain areas.
 Longitudinal neuropsychological and neuroimaging
studies, with neuropathology, are critical, and interactive
research projects are another key element.
w There has been considerable discussion of the
association between education and cognitive decline, and
further research could usefully be directed towards
correlations between factors such as baseline intelligence,
level of education, health, and social class.
Once this information has been accrued one could
envisage a multifactor intervention trial in normal healthy
individuals, the interventions reflecting biological and
behavioural rationale and with due knowledge of any
possible toxicity. 6
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The issue of legal competence arises in dementia-
especially with respect to caring, treatment, and research.
Legal capacity is specific to particular functions or tasks.
There is a low legal threshold of competence to comply
with medical care. Acceptance and rejection of medical
advice are different functions, which creates a paradox.
Patients who comply with treatment can enjoy the
ordinary presumption of competence, whereas refusal of
treatment will raise questions of competence. The law
recognises competent individuals’ rights to make bad
choices, and those not competent cannot usually be
managed by others in ways that they would have objected
to when competent. Carers might have to enact poor
choices in a person no longer competent. Consent to
treatment can only be given by a person capable of giving
it, but an incompetent person can assent (ie, not object)
by being willing to let things happen.
There are legal strategies to address these issues. People
can make plans when they are mildly demented. They can
give directives for their personal care and treatment and
to settle financial matters that will apply when they are
more seriously affected. They can also approve someone
to manage their care, treatment, and financial affairs in
the future. And they can compose directives about
participation in research trials.4
There is no uniform legal framework to cover the
ethical issues and treatment in severe dementia. There are
wide cultural differences with respect to communicating a
diagnosis with a gloomy prognosis. If so informed, an
individual can plan for the future if he is aware of the
outlook, but in some countries doctors prefer to tell only
the relatives the diagnosis, which raises issues about
confidentiality. Another difficulty facing doctors is that of
involving patients in treatment who are not competent to
give informed consent. Here, in severe dementia, the
treating physician is faced with a potential for conflict
between people’s autonomy and beneficence. Should a
patient be given treatment to which he appears not to
assent, even if it is in his perceived best interest? This
conflict could be softened by encouraging individuals
early in their illness to anticipate their incompetence and
indicate what their wishes would be.
Questions of competence arise about participation in
clinical trials and about treatment in dementia. In
instances in which participation in clinical trials is judged
worthwhile, should informed consent be obtained? Or
should investigators withhold information, or inform
unless there is a reason not to at the instigation of a trial?
Should prior consent be obtained when individuals are
competent, in the anticipation that they might take part in
clinical trials later in their illness? Ethics committees vary
greatly in their decisions, and there is huge local variation.
If tissue or blood samples have been obtained for one
purpose, should consent be obtained for other
investigations on those samples? Some investigators have
circumvented this difficulty by obtaining permission to
use samples in a particular area of research, rather than
for a specific project.
Clearly, there is a need for guidelines about research
participants’ consent when competent and compliance
when incompetent to participate in clinical trials, for
proposed interventions, and for the use of tissues in
research.
The issue of genetic testing in dementia is not clearcut.
Little can be done therapeutically, so people cannot
benefit in that way from knowledge of their genetic status.
Legally, individuals are obliged to inform insurance
companies of genetic test results, and their medical, life,
and disability insurance cover might be affected by a
positive result, which in any case can only be measured in
terms of probability. In research, should an individual be
informed of the result at the time or at some time in the
future if such knowledge were appropriate at a later date
(perhaps because of medical advances)? At present,
generally, individuals are not informed, although some
centres do so through the general practitioner. Perhaps we
could learn from experience from other models, such as
low-density lipoprotein testing and cholesterol. More
informed public debate is needed with respect to genetic
testing. Better relations between scientists and the media
might help to ensure that reliable information is passed on
to the public, especially the most important factor in the
genetics of dementia-uncertainty.
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